Targeting actin-bundling protein L-plastin as an anabolic therapy for bone loss
Xiaoqun Li, Lipeng Wang, Biaotong Huang, Yanqiu Gu, Ying Luo, Xin Zhi, Yan Hu, Hao Zhang, Zhengrong Gu, Jin Cui, Liehu Cao, Jiawei Guo, Yajun Wang, Qirong Zhou, Hao Jiang, Chao Fang, Weizong Weng, Xiaofei Chen, Xiao Chen, Jiacan Su
Abstract
vessel growth and bone formation. LPL expression is regulated by the phosphatidylinositol 3-kinase/AKT/specific protein 1 axis in response to receptor activator of nuclear factor-κB ligand. Furthermore, we identified an LPL inhibitor, oroxylin A, that could maintain bone mass in ovariectomy-induced osteoporosis and accelerate bone fracture healing in mice. In conclusion, we showed that LPL regulates osteoclasts fusion, and targeting LPL serves as a novel anabolic therapy for pathological bone loss.
Topics & Concepts
AnabolismActinAnabolic AgentsChemistryBioinformaticsCell biologyBiologyBiochemistryBone Metabolism and DiseasesS100 Proteins and AnnexinsBone health and treatments